ClinicalTrials.gg
Active, not recruitingNCT06427668Updated Aug 17, 2025

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

A Phase 2 interventional study of SPG302 and Placebo in Alzheimer Disease, sponsored by Spinogenix. Active, not recruiting at 2 sites in Australia. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Spinogenix · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 177 studies in Alzheimer Disease with a site in Australia — 23 open to participants now, 42 under way, 18 of them phase 3. Alzheimer Disease · Australia.

Enrollment
156th of 168
24 · median 313
Started
2024
with 10 others
Phase 2
43 of 177
5 open now
Primary completion
2025-12
later than 3 of 41 live
Registered
150th of 177
by date

Among the 177 studies in Alzheimer Disease with a site in Australia, this one is the 156th largest by enrollment of the 168 interventional ones that give a count, is one of 11 that started in 2024, is one of 43 in phase 2, reaches primary completion later than 3 of the 41 other live ones, and was the 150th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

23 of the 177 studies in Alzheimer Disease with a site in Australia are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Alzheimer Disease with a site in Australia, or all of them as a file.
02

Study summary

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

Read the detailed description

This is a phase 2, multicenter study to assess the safety, tolerability, CNS effects, pharmacokinetics, pharmacodynamics and clinical efficacy of SPG302 in adult participants with mild-to-moderate AD. The study will consist of 2 parts:

Part A: Placebo-controlled, randomized, safety and preliminary efficacy cohort with daily dosing for 28 day cycles

Part B: a randomized expansion cohort of daily dosing for 28 day cycles

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer Disease
  • synapse
  • neural connectivity
  • Dementia
04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 45-85
  • Diagnosis of mild to moderate AD
  • Clinical laboratory values within normal range or \< 1.5 times
  • If receiving AD-specific treatment, have been on stable dose for ≥ 3 months prior to first dose of study drug.
  • of >2 years
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Any physical or psychological condition that prohibits study completion
  • Known cardiac disease
  • Active or history of in the past 5 years
  • Serious infection that will not be resolved by first day of study intervention.
  • History of CNS event or diagnosis in the past 5 years.
  • Acute illness within 30 days of Day 1
  • History of suicidal behavior or suicidal ideation
  • History of chronic alcohol use or substance abuse in the last 5 years
  • , and/or positive
  • Vaccines within 14 days
  • Receipt of products within 30 days
  • Blood donation within 30 days
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Part A: Active SPG302 to be administered to adult participants with AD

    Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be 300 mg orally once daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to cohort 2: 12 additional participants pending review of data, for additional dose exploration.

    Drug: SPG302

  • Placebo comparator
    Part A: Placebo comparator to be administered to adult participants with AD

    Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be placebo capsule orally daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to 12 additional participants as cohort 2 pending review of data, for additional dose exploration.

    Drug: Placebo

  • Experimental
    Part B: Expansion Cohort

    Dose to be used and size of dosing cohort to be determined by Data Safety and Monitoring Committee following completion of Part A.

    Drug: SPG302

Interventions

  • DrugSPG302

    synthetic small molecule

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in Electroencephalogram (EEG) at resting state and at auditory evoked P300 from baseline to endpoint

    Electroencephalogram (EEG) will provide non-invasive measurement of brain activity. This test will be used to measure resting state cognitive activity as well as cognitive activity after auditory stimulation. Sound stimuli is 500Hz and 2000Hz.

    Time frame: 8 months

  2. Change in Alzheimer's Disease Assessment Scale-Cog (ADAS-COG) total score from baseline to endpoint

    The Alzheimer's Disease Assessment Scale-Cognitive Subscale test (ADAS-Cog) measures language and memory, focusing on cognitive and non-cognitive functioning. It evaluates word recall, naming of objects, word recognition, comprehension and word finding. The ADAS-COG is scored 0-70. The higher the score the greater the impairment.

    Time frame: 8 months

  3. Change in Mini-Mental State Examination (MMSE) from baseline to endpoint

    The Mini-Mental State Exam (MMSE) is a test of cognitive function. It includes tests of orientation, attention, memory, language and visual-spatial skills. The lower the score the greater the impairment.

    Time frame: 8 months

  4. C-SSRS (Columbia Suicide Severity Rating Scale)

    Prospective suicidality assessment is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire to evaluate suicidal ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section is considered positive. The suicidal behavior lethality sub-scale inquires about the level of actual or potential medical damage.

    Time frame: 8 months

  5. Change in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) from baseline to endpoint

    The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) is a metric for clinical assessment of symptom severity. It consists of 2 parts. First a baseline evaluation of patient and caregiver is performed to collect necessary clinical information. The clinician will then conduct the second phase of the assessment after a specified time period, and changes in symptom severity are indicated on a seven point scale. A higher scale indicates a worsening of symptoms.

    Time frame: 8 months

  6. Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale from baseline to endpoint

    The Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale is an scale that assesses the performance of daily tasks and activities. A lower score indicates lower functional performance.

    Time frame: 8 months

  7. Quality of Life in Alzheimer's Disease (QOL-AD) from baseline to endpoint

    The Quality of Life in Alzheimer's Disease (QOL-AD) is a test to evaluate the quality of life through a series of questions of ability to complete daily activities and tasks. A lower score indicates lower functional quality of life.

    Time frame: 8 months

Secondary outcomes

  1. Safety and tolerability of SPG302

    Incidence, nature and severity of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: 8 months

  2. Plasma pharmacokinetics of SPG302 in participants with AD-Maximum Plasma Concentration (Cmax)

    Blood will be collected following administration of SPG302 and plasma levels will be evaluated to measure the maximum concentration.

    Time frame: 8 months

  3. Change in biomarkers in participants with AD from baseline to endpoint.

    To assess the effect of SPG302 on Neurofilament light (NfL), a protein elevated in AD. This will be measured in picometers/milliliter.

    Time frame: 8 months

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2025, 17 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 17 months is below that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2024
First posted
May 24, 2024
StartActual
Jul 29, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06427668
Lead sponsor
Spinogenix
Responsible party
Sponsor
First posted
May 24, 2024
Start date
Jul 29, 2024
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Aug 17, 2025

Study contacts

Lauren Priest, MBBS
principal investigator · Flinders Medical Center, Adelaide, SA, Australia
Brew Brew, MBBS,MD,DSC
principal investigator · St Vincents Hospital, Sydney, NSW, Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPG-302

Start the discussion